| Genmab A/S |
| 日期/時間 | / |
| 漲跌。 / 漲跌。(%) | - / |
| Bid | - |
| Ask | - |
| 打開 | - |
| 過往收市 | - |
| 高 | - |
| 低 | - |
| 成交量 [DKK] | - |
| 成交量 [Units] | |
| Price fixings | |
| ISIN | DK0010272202 |
| 符號 | GMAB |
| 交易所 | OMX Nordic |
| 類型 | 股票 |
所有交易
| 交易所 | 最後的 | 成交量 | |
|---|---|---|---|
| Lang & Schwa.. | 286,20 |  |
|
| OMX Nordic | 2.130,00 |  |
132.969 |
| Cboe Europe .. | 2.132,00 | |
32.467 |
| Turquoise | 2.131,00 | |
17.915 |
| London Inter.. | 2.131,0 | |
3.018 |
| Nasdaq Other.. | 342,9400 | |
212 |
| Cboe Europe .. | 2.132,50 | |
80 |
| Cboe Europe .. | 2.136,50 | |
69 |
| München | 286,00 | |
20 |
| TradeGate | 287,000 | |
12 |
| Frankfurt | 285,9000 | |
11 |
| Vienna Globa.. | 287,00 | |
0 |
| Düsseldorf | 286,20 | |
0 |
| Berlin | 288,20 | |
0 |
| Stuttgart | 285,800 | |
0 |
| gettex | 285,900 | |
|
| Mexico | 7.638,15 |  |
11.330 |
新聞
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
09.04.2021 / 22:00 - GlobeNewswire - Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
01.04.2021 / 12:45 - GlobeNewswire - Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
31.03.2021 / 12:45 - GlobeNewswire - BioNTech Announces Full Year 2020 Financial Results and Corporate Update
30.03.2021 / 12:30 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
30.03.2021 / 07:21 - GlobeNewswire